• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Synthesis of cis and trans isomers of an isoxazoline ring-hydroxylated metabolite of roxifiban, a platelet glycoprotein IIb/IIIa receptor antagonist.

作者信息

Batt D G, Houghton G C, Daneker W F, Jadhav P K

机构信息

Department of Chemical and Physical Sciences, The DuPont Pharmaceuticals Company, Experimental Station, Wilmington, Delaware 19880-0500, USA.

出版信息

J Org Chem. 2000 Nov 17;65(23):8100-4. doi: 10.1021/jo000755o.

DOI:10.1021/jo000755o
PMID:11073629
Abstract
摘要

相似文献

1
Synthesis of cis and trans isomers of an isoxazoline ring-hydroxylated metabolite of roxifiban, a platelet glycoprotein IIb/IIIa receptor antagonist.罗昔非班（一种血小板糖蛋白IIb/IIIa受体拮抗剂）的异恶唑啉环羟基化代谢产物的顺式和反式异构体的合成。
J Org Chem. 2000 Nov 17;65(23):8100-4. doi: 10.1021/jo000755o.
2
Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.罗昔非班（一种强效且选择性的血小板糖蛋白IIb/IIIa受体拮抗剂）代谢产物的质谱和核磁共振表征
Xenobiotica. 2000 Nov;30(11):1091-110. doi: 10.1080/00498250010006591.
3
Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.小分子RGD模拟物的血小板糖蛋白IIb/IIIa结合特性：罗昔非班独特的结合图谱
Br J Pharmacol. 2001 Jun;133(3):331-6. doi: 10.1038/sj.bjp.0703943.
4
Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations.在存在毫摩尔浓度干扰置换剂的情况下，采用液相色谱/串联质谱法同时定量测定人血浆中罗昔非班的七种活性代谢物。
J Pharm Biomed Anal. 2003 Apr 1;31(5):937-51. doi: 10.1016/s0731-7085(02)00675-1.
5
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.新型口服血小板糖蛋白IIb/IIIa受体抑制剂罗昔非班（DMP754）在稳定型冠状动脉疾病患者中的应用。
Am J Cardiovasc Drugs. 2003;3(2):101-12. doi: 10.2165/00129784-200303020-00004.
6
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.糖蛋白IIb/IIIa拮抗剂roxifiban与orbofiban在血栓形成血流模型中抑制血小板反应的疗效比较。
J Cardiovasc Pharmacol. 2002 Apr;39(4):552-60. doi: 10.1097/00005344-200204000-00011.
7
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.不同血小板糖蛋白IIb/IIIa拮抗剂对剪切诱导的血小板活化和黏附的比较分析
J Pharmacol Exp Ther. 2002 Dec;303(3):1114-20. doi: 10.1124/jpet.102.038513.
8
Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.强效异恶唑啉糖蛋白IIb/IIIa受体拮抗剂的发现。
J Med Chem. 1997 Jan 3;40(1):50-60. doi: 10.1021/jm960626t.
9
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.使用血栓弹力图来确定血小板糖蛋白IIb/IIIa拮抗剂罗昔非班对人体血小板/纤维蛋白介导的凝血动力学的疗效。
Blood Coagul Fibrinolysis. 2005 Apr;16(3):165-71. doi: 10.1097/01.mbc.0000164423.90545.a0.
10
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).在罗昔非班口服复合动力学评估试验-I（ROCKET-I血小板亚研究）中，罗昔非班对冠心病患者血小板聚集及主要受体表达的影响。
Am Heart J. 2003 Jul;146(1):91-8. doi: 10.1016/S0002-8703(03)00186-8.

引用本文的文献

1
Nitrile Oxide, Alkenes, Dipolar Cycloaddition, Isomerization and Metathesis Involved in the Syntheses of 2-Isoxazolines.涉及硝酮、烯烃、偶极环加成、异构化和易位反应的 2-异恶唑啉合成。
Molecules. 2023 Mar 10;28(6):2547. doi: 10.3390/molecules28062547.
2
The Synthesis and Evaluation of Amidoximes as Cytotoxic Agents on Model Bacterial Strains.偕胺肟作为对模型细菌菌株具有细胞毒性的药剂的合成与评估
Materials (Basel). 2021 Dec 9;14(24):7577. doi: 10.3390/ma14247577.